Videos

Veena Joy, MS, discusses Thermo Scientific’s recent FDA approval of their EliA SmDP-S test, which aides in the diagnosis of Systemic Lupus Erythematosus (SLE).

Sarah Stewart, PhD, discusses her study entitled "What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout."

Jason Kolfenbach, MD, discusses his CCR West presentations entitled “Common Eye Disorders in Rheumatology Clinic” and “Top Secrets in Rheumatology.”

Philip Conaghan, MBBS, PhD, discusses his presentation entitled, “Meaningful Improvements in WOMAC Pain and Physical Function in 3 Phase 3 Trials of Tanezumab in Patients With Moderate-to-Severe Osteoarthritis: A Responder Analysis.”

Susan Chrostowski, DNP, MS, APRN discusses her presentation, entitled “Demystifying Fibromyalgia for the Nurse and Advanced Practice Provider.”

The stigma surrounding gout has contributed to the general unease patients have about their condition.

Daniel Hernandez, MD, and Esteban Rivera discuss the study, “Social Listening: Factual vs. Misinformation YouTube Spanish-Language Rheumatoid Arthritis Videos,” presented at the 23rd Pan-American Conference of Rheumatology (PANLAR) 2021.

Dr. LaMoreaux believes that to treat gout in patients with proper medications and therapies, doctors must first establish trust and combat the stigma surrounding this painful form of arthritis.

Bryant England, MD, discusses his presentation entitled, “Epidemiology of Multimorbidity in Rheumatoid Arthritis."

John Cush, MD, discusses his upcoming lecture entitled, “Rheumatoid Arthritis: Year in Review,” which will be presented at the Congress of Clinical Rheumatology.

Randall Cron, MD, PhD, discuss his lectures entitled, “The Immunology of COVID” and “The Role of Rheumatologists in COVID-19,” which will be presented at the Congress of Clinical Rheumatology.

Brian LaMoreaux, MD, MS, discusses the recent study entitled, "Improving outcomes for patients hospitalised with gout: a systematic review."

Dr. Blauvelt speaks on the results of the phase 3b Heads Up study, and the future of upadacitinib and dupilumab in atopic dermatitis management.

Alexis Ogdie-Beatty, MD, discusses the UPLIFT survey and UPLIFT Innovation Challenge, the unmet needs of patients with psoriatic arthritis, and the clinical significance of the survey’s results.

Leonard Calabrese, DO, discusses his findings entitled, “Applied Immunology to Autoimmune Diseases: COVID-19 as Immunology,” which was presented at the Rheumatology Nurses Society Conference.

Richard Furie, MD, discusses the recent FDA approval of anifrolumab-fnia for the treatment of patients with systemic lupus.

Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.

Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.

Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.

Eric Morand, MD, PhD, explains why rheumatologists failing in lupus while succeeding so spectacularly in diseases like rheumatoid arthritis and what needs to change.

Treatment of the osteoarthritis has been at a standstill, with short-term pain management with steroid injections considered standard care. However, a promising new therapeutic approach may help to sustain pain relief over time.

Rheumatology Network sat down with Mehret Birru Talabi, MD, PhD, to discuss the recent study published in ACR Open Rheumatology entitled, “Tough choices: Exploring medication decision-making during pregnancy and lactation among women with inflammatory arthritis.”

Jeffrey Stark, MD, discusses the statement UCB issued endorsing the creation of a new sub-category (M.45A) for non-radiographical axial spondyloarthritis (nr-axSpA).

In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.

Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.

Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."

Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.

Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.